Abstracts tagged "patient outcomes and monoclonal antibodies"

Abstract Number: 434 • ACR/ARP Annual Meeting 2019
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
Cheng-Chung Wei¹, Theresa Hunter ², Filip Van den Bosch ³, Jessica Walsh ⁴, Uta Kiltz ⁵, Yan Dong ⁶, David Sandoval ⁶, Luis Leon ⁶, Vibeke Strand ⁷ and Xiaoqi Li ², ¹Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ²Eli Lilly and Company, Indianapolis, ³Ghent University Hospital, Ghent, Belgium, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Previous trials have used the Short Form (SF)-36 questionnaire to evaluate the impact of ankylosing spondylitis/radiographic axial spondyloarthritis (AS/r-axSpA) on health-related quality of life…